NCT04053283 - First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

January 23, 2020

Primary Completion Date

August 31, 2023

Study Completion Date

December 20, 2023

Conditions

Metastatic CancerEpithelial Tumor

Interventions

BIOLOGICAL

NG-641

NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.

Trial Locations (6)

34747

Moffitt-Advent Health Clinical Research Unit, Celebration

63110

Washington University Medical School, St Louis

77030

MD Anderson, Houston

90033

University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles

93105

UCLA, Santa Barbara

70121-2429

Ochsner Medical Center (OMC) - The Gayle and Tom Benson Cancer Center, New Orleans